来氟米特
5-METHYLISOXAZOLE-4-(4-TRIFLUOROMETHYLCARBOXANILIDE);5-METHYL-N-[4-(TRIFLUOROMETHYL)PHENYL]-4-ISOXAZOLECARBOXAMIDE;ALPHA,ALPHA,ALPHA-TRIFLUORO-5-METHYL-4-ISOXAZOLECARBOXY-P-TOLUIDIDE;HWA 486;LEFLUNOMIDE N-(4-TRIFLUOROMETHYLPHENYL)-5-METHYLISOXAZOL-4-CARBOXAMIDE;5-methylisoxazole-4-carboxylicacid(4-trifluoromethyl)anilide;5-methyl-n-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamid;LeflunamideAnti-Rheumatic;Leflunamide;α,α,α-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide;4-Isoxazolecarboxamide, 5-methyl-N-[4-(trifluoromethyl)phenyl]-;LEFLUNOMIDE(SUBJECTTOPATENTFREE);5-METHYL-N-(4-(TRIFLUOROMETHYL)PHENYL)ISOXAZOLE-4-CARBOXAMIDE;5-Methylisoxazole-4-[4-trifluoromethylcarboxanilide]q;Arava;Isoxazol lefunomide;RS-34821;Leflunomide;5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide;5-Methyl-N-[4-(trifluoromethyl)-phenyl]isoxazole-4-carboxamide;Leflunomid;Leflunomida;Leflunomidum;lefunamide;N-(4-trifluoromethyl-phenyl)-5-methylisoxazole-4-carboxamide;SU101;5-Methylisoxazole-4-(4-trifluoromethyl)carboxanilide;5-Methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide;LEFLUNOMIDE [MI];NCGC00015610-05;KBio2_003370;NCGC00015610-14;LEFLUNOMIDE (EP MONOGRAPH);HMS2097K06;HWA486;NCGC00022625-06;Lopac-L-5025;BDBM50054601;NINDS_000916;HMS3268D12;Prestwick0_000772;LEFLUNOMIDE (USP MONOGRAPH);DL-433;Opera_ID_1709;NCGC00022625-04;N-(4-trifluoromethylphenyl)-5-methylisoxa-zole-4-carboxamide;Prestwick3_000772;Tox21_301873;5-methylisoxazole-4-carboxylic acid trifluoromethylanilide;HMS3865I13;NCGC00015610-01;NCGC00015610-08;NCGC00015610-17;Leflunomide, Pharmaceutical Secondary Standard; Certified Reference Material;NSC677411;HMS3714K06;NCGC00261334-01;Leflunomide, European Pharmacopoeia (EP) Reference Standard;LEFLUNOMIDE (MART.);HMS1922M06;Leflunomida [INN-Spanish];Leflunomide ratiopharm;KS-1076;5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide;Leflunomide 100 microg/mL in Acetonitrile;L0250;Leflunomida (INN-Spanish);Leflunomidum (INN-Latin);AB00052389;AB00052389-18;AB00052389_21;HMS1570K06;4-Isoxazolecarboxamide, 5-methyl-N-(4-(trifluoromethyl)phenyl)-;NCGC00015610-10;Spectrum_000322;SPBio_002783;Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard;Q248550;NCGC00015610-12;NCGC00022625-05;GTPL6825;Pharmakon1600-01503927;BPBio1_000930;5-methyl-N-(4-(trifluoromethyl)phenyl)-1,2-oxazole-4-carboxamide;IDI1_000916;Lefunomide [Inn-Spanish];AB00052389-17;SULOL;5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide;G162GK9U4W;NSC759864;MLS000069648;BRD-K78692225-001-03-9;AKOS000265193;LEFLUNOMIDE [EP MONOGRAPH];5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide;SU 101 (pharmaceutical);BRD-K78692225-001-11-2;AB00052389_19;SU-101;L04AA13;CHEBI:6402;HMS3678N21;5-Methylisoxazole-4-(4-trifluoromethylcarboxanilide);NCGC00015610-30;LP00649;LEFLUNOMIDE [USAN];L 5025;Lopac0_000649;HMS2090O...